Streetbeat News

Partnerships

ADIL

Traders are circulating unconfirmed analyst comments about Adial Pharmaceuticals (ADIL), suggesting that the company's management is in advanced discussions with a large pharma partner for the addiction marketplace in the U.S., EU, or both. The comments also include a buy rating with a $21 price target (PT).

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:13 pm

BHP

COPP

JIAXF

NEM

SLGGF

Ecuador announced a $3.2 billion investment in SolGold's Cascabel copper-gold project, marking a significant move in the country's mining sector. This investment aims to leverage the growing copper market amid supply constraints. SolGold, which saw its shares surge 23%, also revealed a reduction in upfront costs for the project and signed an MoU for a potential carbon-neutral power supply. Major stakeholders in SolGold include BHP, Newmont, and Jiangxi Copper, with the Sprott Copper Miners ETF also related to the copper industry.

Portfolio Pulse from Stjepan Kalinic

March 07, 2024 | 2:29 pm

EPOW

EPOW has received an order for 25,000 tons of energy storage materials from Xiamen HiTHIUM Energy Storage Technology Co., Ltd., marking a significant business development for the company.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:26 pm

EVGN

Evogene Ltd. (NASDAQ:EVGN) reported a 237% increase in annual revenue for 2023, totaling $5.6 million, despite a 12% decrease in Q4 revenue year-over-year. The company highlighted its successful collaborations and is considering transferring its medical cannabis subsidiary, Canonic Ltd., to a third party due to challenging market conditions. Despite these developments, Evogene's shares dropped 4.43% in pre-market trading.

Portfolio Pulse from Jelena Martinovic

March 07, 2024 | 2:20 pm

CYH

Community Health Systems, Inc. (CHS) has partnered with Mark Cuban Cost Plus Drug Company to purchase select pharmaceutical supplies, marking CHS as the first national healthcare system to do so. This collaboration aims to bring high-quality, lower-cost drugs to the hospital setting, starting with CHS-affiliated hospitals in Texas and Pennsylvania. The partnership coincides with the opening of Cost Plus Drugs' new drug manufacturing plant in Dallas, Texas. The initiative addresses rising pharmaceutical costs, drug shortages, pharmaceutical waste, and patient safety by offering drugs at minimal mark-up and in flexible ordering options.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:12 pm

GM

RTX

Neural Propulsion Systems (NPS) has secured a $17.5 million Series B funding round led by Cota Capital, with contributions from GM Ventures and RTX Ventures. The funding will be used to develop NPS's Atomic Sensing Platform for automotive radar technology, aiming to enhance road safety and defense radar systems. The technology promises over 10 times the performance of current radar capabilities, potentially revolutionizing the $28 billion radar market.

Portfolio Pulse from Anusuya Lahiri

March 07, 2024 | 2:10 pm

LEXX

Lexaria Bioscience has engaged a Contract Research Organization to conduct its upcoming GLP-1 human pilot study. This move indicates Lexaria's commitment to advancing its research and development efforts in the medical field.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:08 pm

AER

AerCap has entered into a component agreement with OEMServices, aiming to enhance its service offerings. This partnership is expected to bolster AerCap's capabilities in providing comprehensive component solutions to its customers.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:07 pm

SEDG

SolarEdge Technologies, Inc. (NASDAQ:SEDG) has announced an investment and partnership with AMPEERS ENERGY, a German software start-up focused on decarbonizing multi-dwelling buildings. This collaboration aims to combine SolarEdge's solar and smart energy technology with AMPEERS's platform to offer a comprehensive photovoltaic tenant electricity solution for real estate companies. The solution includes planning, implementation, and financing of solar and storage generation, tenant electricity billing, EV charging, and new heating technologies. This strategic move is designed to capitalize on legislative changes in Germany and expand into the multi-dwelling market across Europe.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:04 pm

APVO

ATORX

Alligator Bioscience (ATORX) and Aptevo Therapeutics (NASDAQ:APVO) announced positive interim data from their Phase 1 trial of ALG.APV-527 for solid tumors expressing 5T4. The trial showed favorable drug exposure, confirmed biological activity, and early signs of clinical activity in heavily pretreated patients. The trial is over 50% enrolled, with dose escalation ongoing. Both companies highlighted the potential of ALG.APV-527 in treating multiple tumor types and expressed optimism for future development.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 1:59 pm